Peter Voorhees, MD of the Levine Cancer Institute in Charlotte, NC provides an update on the Griffin Study, a Phase 2 clinical trial comparing subcutaneous daratumumab in combination with standard-of-care regimens for newly diagnosed multiple myeloma.
Daratumumab is an IgGκ monoclonal antibody targeting CD38 that is approved as monotherapy and in combination with standard-of-care regimens for multiple myeloma. The data presented by Dr. Voorhees at the American Society of Hematology (ASH) Annual Meeting in Orlando, FL is showing that the addition of daratumumab to standard of care regimens improves response rates, depth of response, including stringent complete response (sCR) rate and minimal residual disease (MRD) negativity. Details of the data presented at ASH can be found here.
Multiple myeloma is a rare blood cancer characterized by the expansion of malignant plasma cells in the bone marrow associated with excessive production of monoclonal immunoglobulins in blood and urine. Individuals with multiple myeloma develop significant osteolytic bone lesions and have immunodeficiency that compromise their longevity and quality of life. Numerous treatment options are available for this population but newer, safer, and more effective treatments are in great demand.
For more information about this and other rare blood disorders, visit https://checkrare.com/diseases/blood-diseases/